Barclays’s IGC Pharma IGC Stock Holding History

Barclays’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-537	Closed	-$1K	–	4957
2021 Q1	$1K	Buy	+537	New	+$976	﹤0.01%	4593
2020 Q3	–	Sell	-6,386	Closed	-$4K	–	5368
2020 Q2	$4K	Buy	+6,386	New	+$3.46K	﹤0.01%	5401
2019 Q3	–	Sell	-100	Closed	–	–	6891
2019 Q2	$0	Buy	+100	New	+$141	﹤0.01%	7072

Other funds holding IGC

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Dearborn Partners Chicago, Illinois $1.85B AUM 6.59% 1-Year Est. Return

Barclays's IGC Position: Q2 2021 in Review

Barclays sold out of IGC Pharma (IGC) in Q2 2021, closing a stake of 537 shares — an estimated $1K sold.

Barclays first reported a position in IGC in Q2 2019 and held it in 3 quarters. The position peaked at $4K in Q2 2020. 29 funds tracked by Wall St. Rank hold IGC as of Q2 2021.

Barclays reported no remaining IGC Pharma position as of Q2 2021 after selling out during the quarter.
Barclays sold 537 IGC Pharma shares in Q2 2021, an estimated $1K.
Barclays first reported a position in IGC Pharma in Q2 2019 and held it in 3 quarters.
Barclays's IGC Pharma position peaked at $4K in Q2 2020.
29 funds tracked by Wall St. Rank held IGC Pharma as of Q2 2021.

Based on Barclays's 13F filing for Q2 2021, filed 13 Aug 2021.